Valion Bio, Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
VBIO$0.54+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(in thousands, except share and per share data)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $780 | $1,176 |
| Cost of sales | 778 | 889 |
| Gross profit | 2 | 287 |
| Operating expenses: | ||
| Research and development | 1,313 | 1,655 |
| Sales and marketing | 1,187 | 2,125 |
| General and administrative | 3,163 | 4,752 |
| Total operating expenses | 5,663 | 8,532 |
| Loss from operations | (5,661) | (8,245) |
| Other income: | ||
| Interest income | 6 | 1 |
| Total other income | 6 | 1 |
| Net loss | $(5,655) | $(8,244) |
| Net loss per share - basic and diluted | $(19.68) | $(176.80) |
| Weighted-average number of shares - basic and diluted | 287,370 | 46,650 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.